BLEEDnFIRE Therapeutics is a biotech company developing first-in-class RNAi therapies to rebalance hemostasis in severe bleeding disorders. Our lead program, BnF-001, selectively targets a hepatic anticoagulant to provide durable bleed protection without factor replacement, addressing key limitations of current therapies. The approach is particularly provide safe and durable treatment for patients underserved by existing treatments. BLEEDnFIRE holds granted IP in the USA, Canada, Japan, and South Korea. The founding team combines complementary expertise in hematology, RNA therapeutics, translational medicine, and biotech entrepreneurship, positioning the company for efficient clinical translation and global partnering.